Nrf1 is not a direct target gene of SREBP1, albeit both are integrated into the rapamycin-responsive regulatory network in human hepatoma cells

The essential role of protein degradation by ubiquitin-proteasome system is exerted primarily for maintaining cellular protein homeostasis. The transcriptional activation of proteasomal genes by mTORC1 signaling depends on Nrf1, but whether this process is directly via SREBP1 remains elusive. In this study, our experiment evidence revealed that Nrf1 is not a direct target of SREBP1, although both are involved in the rapamycin-responsive regulatory networks. Closely scrutinizing two distinct transcriptomic datasets unraveled no significant changes in transcriptional expression of Nrf1 and almost all proteasomal subunits in either siSREBP2-silencing cells or SREBP1–∕–MEFs, when compared to equivalent controls. However, distinct upstream signaling to Nrf1 dislocation by p97 and its processing by DDI1/2, along with downstream proteasomal expression, may be monitored by mTOR signaling, to various certain extents, depending on distinct experimental settings in different types of cells. Our further evidence has been obtained from DDI1–∕–(DDI2insC) cells, demonstrating that putative effects of mTOR on the rapamycin-responsive signaling to Nrf1 and proteasomes may also be executed partially through a DDI1/2-independent mechanism, albeit the detailed regulatory events remain to be determined.


Introduction
The normal homeostasis must have to be maintained in all healthy life forms, due to homeostasis robustness, plasticity and resilience ensuring that their structural organization, physiological function and biological behavior are being properly performed and perpetuated at a stable, robust steady-state [1].Conversely, defects in the maintenance of cell fitness and homeostasis have emerged as an underlying feature of a vast variety of pathologies, such as cancer, senescence and aging-related diseases [2][3][4].Of note, protein homeostasis (i.e.proteostasis) is preserved or not, depending on a steady balance between protein synthesis and turnover [5,6].Interestingly, as reported by Manning's group [7], such a finely-programmed balance between protein synthesis and degradation was coordinately regulated by the mechanistic target of rapamycin complex 1 (mTORC1), a central kinase that is generally activated by cell growth-and proliferation signaling to trigger protein translation [8].Besides, they had also shown that mTORC1 signaling activates transcriptional expression of nuclear factor erythroid 2-related factor 1 (Nrf1 with multiple isoforms, encoded by NFE2L1) directly by sterol regulatory element-binding protein 1 (SREBP1) [7,9], although SREBP1 has been commonly accepted as a key control of lipid synthesis and membrane homeostasis, even in response to the rather multifaceted mTOR signaling [10][11][12].
Intriguingly, in the present study, our evidence has been presented revealing that Nrf1 is not a direct target of SREBP1, albeit they are involved in the rapamycin-responsive regulatory networks.Further experiments are designed to determine whether p97, DDI1 (also called VSM1 (v-SNARE binding protein-1)), which is a highly conserved aspartyl protease among all eukaryotes from yeast to human [13][14][15] and DDI2 (only present in vertebrates [16]) exert the putative rapamycin-responsive effects on Nrf1 processing and activity to regulate the proteasomal expression.Moreover, the human HepG2-derived DDI1 -∕-(DDI2 insC ) cell line and tumor xenograft model have also been established herein, to further elucidate the rapamycin-responsive effects on Nrf1 and cognate proteasomes.

Cell culture and treatments
HepG2 and HL7702 cell lines were grown in DMEM supplemented with 5 mM glutamine, 10% (v/v) fetal bovine serum (FBS), 100 units/ml of either penicillin or streptomycin, in a 37˚C incubator with 5% CO 2 .Additional HepG2-derived cell lines with the knockout of DDI1 -∕-were herein established by CRISPR-editing of DDI1 with specific gRNA (S1 Table in S2 File).The authenticity of DDI1 -∕-cells had been confirmed by its authentication analysis.Thereafter, experimental cells were transfected with a Lipofectamine 3000 mixture with indicated plasmids or siSREBP1 (with a pair of sequences, S1 Table in S2 File) for 8 h, and allowed for recovery from transfection in a fresh medium for 24 h before being experimented.Additional cells were treated with the mTOR inhibitor rapamycin (RAPA, 20 to 200 nM) or proteasomal inhibitor MG132 (1 to 10 μM) for different time periods (4, 16 or 24h).

Expression constructs
An expression construct for human SREBP1 was made by cloning its full-length cDNA sequence into the pcDNA3 vector, with a pair of its forward and reverse primers (S1 Table in S2 File), which were synthesized by Sangon Biotech Co. (Shanghai, China).Another expression plasmid of Nrf1 was reported previously [17].The fidelity of all these constructs was confirmed to be true by sequencing.

Luciferase reporter assay
After experimental cells (1.0 × 10 5 ) were allowed for growth in each well of the 12-well plates to reach 80% confluence, they were co-transfected with a Lipofectamine 3000 mixture with pNrf1-luc or pNrf2-luc established by Qiu et al. [18], plus other expression plasmids.In this dual reporter assay, the Renilla expression by pRL-TK served as an internal control for transfection efficiency.The resulting data were normalized from at least three independent experiments, each of which was performed in triplicate, and thus shown as a fold change (mean ± S.D) relative to the control values.

Quantitative real-time PCR
About 500 ng of total RNAs from experimental cells were subjected to reverse-transcriptase reaction to generate the first strand of cDNA.The newly-synthesized cDNA was used as the template for quantitative PCR in the Master Mix, before being deactivated at 95˚C for 10 min, and amplified by 40 reaction cycles of annealing at 95˚C for 15 s and then extending at 60˚C for 30 s.The final melting curve was validated to examine the amplification quality.While βactin mRNA level was employed as an optimal internal standard control, target gene expression levels were determined by quantitative real-time PCR, as described previously [19], with each pair of the indicated primers (S1 Table in S2 File).The resulting data were shown a fold change (mean ± S.D) relative to the control values.

Western blotting with distinct antibodies
Total cell lysates in a lysis buffer (0.5% SDS, 0.04 mol/L DTT, pH 7.5) with protease and phosphatase inhibitors (each of cOmplete and PhosSTOP EASYpack tablets in 10 ml buffer), were denatured immediately at 100˚C for 10 min, sonicated sufficiently, and diluted in 3× loading buffer (187.5 mmol/L Tris-HCl, pH 6.8, 6% SDS, 30% Glycerol, 150 mmol/L DTT, 0.3% Bromphenol Blue) at 100˚C for 5 min.Subsequently, equal amounts of protein extracts were subjected to separation by SDS-PAGE containing 4-15% polyacrylamide, and then visualization by Western blotting with distinct antibodies as indicated (S1 Table in S2 File).Some of the blotted membranes were stripped for 30 min and re-probed with additional primary antibodies.Therein, β-actin or GAPDH served as an internal control to verify equal loading of proteins.

Subcutaneous tumor xenograft model
Mouse xenograft models were made by subcutaneously heterotransplanting human HepG2 or derived DDI1 -∕-cells.Briefly, equal amounts of cells (1 × 10 7 ) growing in the exponential phase was suspended in 0.1 ml of serum-free medium and then inoculated subcutaneously at a single site in the right upper back region of male nude mice (BALB/C nu/nu, 4-6 weeks, 18 g).The procedure of injection into all the mice was completed within 30 min.Thereafter, the formation of murine subcutaneous tumor xenografts was successively observed until they were sacrificed.These transplanted tumors were excised immediately after being executed, and also calculated in size by a standard formulate (V = ab 2 /2).All mice were maintained under standard animal housing conditions with a 12-h dark cycle and also allowed access ad libitum to sterilized water and diet, according to the institutional guidelines for care and use of laboratory animals with a license SCXK (JING) 2019-0010.All experimental procedures were approved by the Ethics Committee of Chongqing Medical University.

Pathohistology with H&E staining
The xenograft tumor tissues were immersed in 4% paraformaldehyde overnight and then transferred to 70% ethanol.In processing cassettes, tumor tissues were dehydrated by a serial alcohol gradient and then embedded in paraffin wax blocks, before being sectioned into a series of 5-μm-thick slides.Subsequently, the tissue sections were de-waxed in xylene, rehydrated through decreasing concentrations of ethanol and washed in PBS, before being stained by routine hematoxylin and eosin (H&E) and visualized by microscopy.The resulting images were photographed herein.

Statistical analysis
Significant differences were statistically determined using the Student's t-test and Multiple Analysis of Variations (MANOVA), except for somewhere indicated.The data are here shown as a fold change (mean ± S.D.), each of which represents at least three independent experiments that were each performed in triplicate.

Transcriptional expression of Nrf1 is unaffected by SREBP1
Based on the data obtained from chromatin immunoprecipitation (ChIP) [7] and microarray [20,21], Manning's group considered that aberrant activation of mTOR in TSC2 -∕-MEFs led to upregulation of Nrf1 by SREBP1.However, we showed that transcriptional expression of Nrf1 was unaffected by SREBP1 knockdown or overexpression in both HepG2 and 7702 cell lines (Fig 1A to 1D).Almost no changes in transactivation of Nrf1 or Nrf2 promoter-driven luciferase reporters (pNrf1-luc and pNrf2-luc, established by Qiu et al. [18]) were determined in the cellular response to rapamycin (RAPA), but they were induced by tert-butylhydroquinone (tBHQ, a pro-oxidative stressor) rather than the antioxidant N-Acetyl-L-cysteine (NAC) (Fig 1E to 1H).Such discrepancy may result from a strange disparity in the cytosolic to the nuclear distribution of Nrf1 examined by Manning's lab (S1A Fig in S2 File, cropped from their extended data [7]).This is due to the authors showing abnormal accumulation of a peculiar nuclear Nrf1 isoform with a higher molecular weight than its cytosolic isoform, which is never recovered by all relevant subcellular fractionation experiments (cropped in S1B to S1D Fig in S2 File, as reported by our and other groups) [22][23][24][25].Such strange nuclear Nrf1 accumulation revealed by Manning's group seems to challenge against the well-established spatiotemporal character of this ER-localized transcription factor [26,27].
Intriguingly, further examination showed that abundances of all Nrf1 isoforms were marginally enhanced by silencing of SREBP1 (Fig 2A, cf.a2 vs a1).Accordantly increased mRNA levels of Nrf1-target PSMB6, PSMB7 and PSMB5 (encode the core proteasomal ß1, ß2 and ß5 subunits, respectively [28]) were accompanied by enhanced protein abundances of PSMB6, PSMB7 and slightly PSMB5, concomitantly with SREBP1 knockdown (Fig 2B and 2D).The difference between protein and mRNA levels of PSMB5 (as a key housekeeper in the ubiquitin-proteasomal system) suggests that its protein stability may be finely tuned by the proteasomal feedback regulatory loop, facilitating proteostasis maintenance.Conversely, phosphorylated S6 kinase 1 (pS6K1, required for protein synthesis) protein and mRNA expression levels were significantly down-regulated by siSREBP1 (Fig 2B and 2D).Thereby, SREBP1 may be directionally responsible for regulating protein synthesis and degradation.
Next, an examination of siSREBP1's effects on the upstream regulators of Nrf1 revealed that evident abundances of DDI1 and DDI2 were increased (Fig 2C).This was accompanied by modest decreases in p97/VCP protein and mRNA levels, while the ER-resident E3 ligase Hrd1 was almost unaffected by silencing of SREBP1 (Fig 2C and 2D).Further scrutinizing two distinct transcriptomic datasets (at https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc= GSE93980 and = GSE90571) unraveled that, though putative SREBP1-binding sites exist in both the promoter region of Nrf1 and its first exon (S2 Fig in S2   .(E to H) HepG2 cells, that had been transfected with pNrf1-luc (E, F) or pNrf2-luc siSREBP2-silencing PANC-1 cells or SREBP1 -∕-MEFs, when compared to their wild-type controls.Collectively, these lines of evidence together demonstrate that Nrf1 is not a direct target of SREBP1, albeit its indirect effects on upstream signaling to Nrf1 cannot be ruled out.

Discrete effects of rapamycin on the signaling to Nrf1 and proteasome
It was, to my surprise, found that stimulation of HepG2 cells by feeding 10% FBS after 10-h free-serum starvation caused significant decreases in mRNA expression levels of Nrf1 and SREBP1, but their protein abundances were strikingly increased to varying extents (Fig 3A vs 3B and 3C), and markedly diminished or abolished by rapamycin (20 nM, Fig 3B and 3C).Similar results were obtained for S6K (Fig 3C and 3D).Of note, mRNA expression of S6K, but not Nrf1 or SREBP1, was reversed and increased by rapamycin (Fig 3D).Together, these demonstrate that mTOR is likely involved in at least two different mechanisms for regulating Nrf1 and SREBP1 at mRNA and protein expression levels, which are distinctive from controlling its downstream S6K1 by potential 'bounce-back' response to mTOR inhibitor.
Further experimental evidence showed that Nrf1-target PSMB5, PSMB6 and PSMB7 (Fig 3B ), as well as the upstream signaling DDI1, DDI2, p97 and Hrd1 (Fig 3E ) were significantly upregulated by feeding FBS, of which all those except Hrd1 were also inhibited by rapamycin.However, their mRNA expression levels were down-regulated or unaffected by FBS, but also partially reversed or event enhanced by rapamycin (Fig 3F , cf. left vs right panels).Of note, mRNA expression of PSMB6 and DDI2 was unaltered or down-regulated by FBS, respectively, but both were also significantly augmented by rapamycin.Overall, these results further indicate that key upstream and downstream signaling molecules of Nrf1 were, to some certain extent, influenced by mTOR involved in distinct hierarchical mechanisms.

Alteration in the putative processing of Nrf1 in DDI1/2-deficient cells
Since Nrf1 and C. elegans SKN-1A are activated by DDI1 in the proteasomal 'bounce-back' response [14,17,19] Assessment of subcutaneous tumor xenograft mice unraveled that no differences in in vivo tumorigenesis and tumor growth of DDI1 -∕-(DDI2 insC ) cells were observed when compared to those of its parent wild-type cells (Fig 4D and 4E).Also, no obvious changes in their tumor pathohistological sections were shown (in Fig 4F).Such DDI1/2-deficient cells were then treated with distinct concentrations of MG132 and subjected to determination of (G, H) reporters, along with pRL-TK (an internal control) and then treated for 24 h with rapamycin (RAPA, at 0, 100 or 200 nM) (E, G), NAC (10 mM) or tBHQ (50 μM) (F, H), were subjected to an assay of dual-luciferase activity (n = 3×3) with significant increases ($, p<0.01) or no significances (NS).All the results representing at least three independent experiments, each of which was performed in triplicates, were determined as fold changes (mean ± S.D.) relative to equivalent controls.https://doi.org/10.1371/journal.pone.0294508.g001putative effects of DDI1 -∕-(DDI2 insC ) on the processing of Nrf1.As anticipated, the results revealed that processed Nrf1 isoforms-C/D were significantly reduced, but its full-length glycoprotein-A and deglycoprotein-B were almost unchanged following treatment of DDI1 -∕-(DDI2 insC ) with a lower dose (1 μM) of MG132 when compared to those measured from wild-type cells (Fig 4G, middle two lanes).By sharp contrast, a higher dose (10 μM) of MG132 treatment of DDI1 -∕-(DDI2 insC ) caused Nrf1 isoforms-C/D to be further diminished or abolished, but its full-length proteins-A/B were not augmented, when compared to their wild-type controls (Fig 4G, right two lanes).These demonstrate a requirement of 26S proteasome for DDI1/2-directed proteolytic processing of Nrf1 because the stability of both proteases per se is also controlled by ubiquitin-proteasome pathways [30,31].However, endogenous Nrf1 isoforms-A/B was marginally reduced in untreated DDI1 -∕-(DDI2 insC ) cells, where Nrf1 isoforms-C/D were rather faint to be distinguishable from wild-type controls (Fig 4G, left two lanes).This implies that Nrf1α-derived isoforms may be much unstable to be rapidly destructed, but shorter isoforms Nrf1 ΔN , Nrf1ß and Nrf1γ were unaffected, in DDI1/2-deficient cells (Fig 4G, left two lanes).Such seemingly-contradictory data, showing no increased full-length Nrf1 isoforms-A/B in DDI1 -∕-(DDI2 insC ) cells, suggest that ER membrane-associated protein degradation and/or autophagy [32] may also be triggered in possibly 'bounce-back' response to DDI1/2 deficiency.
Intriguingly, wild-type DDI1 and its short isoform in DDI1 -∕-(DDI2 insC ) cells were not enhanced, but slightly reduced by treatment of 1 μM or 10 μM MG132 for 4 h (Fig 4H , h1), and the reduced abundances were further decreased as treatment time was extended to 24 h (Fig 4H , h4) when compared with their untreated controls.By contrast, wild-type DDI2 and its remaining protein in DDI1 -∕-(DDI2 insC ) cells were largely unaffected by 24-h treatment of 1 μM or 10 μM MG132 (Fig 4H , h5), but after 4-h treatment of cells, they became marginally reduced by 1 μM MG132, and also rather augmented by 10 μM MG132 (Fig 4H , h2).Such distinct effects of this proteasomal inhibitor on DDI1 and DDI2 demonstrate that both protease stability may be governed through different mechanisms, albeit these details remain to be elucidated.

Fig 3. Distinct effects of rapamycin on FBS-altered expression of SREBP1, Nrf1 and relevant signaling molecules. (A) HepG2 cells that had
been starved in a serum-free medium for 10 h and then stimulated for 12 or 24 h by feeding 10% FBS, were subjected to real-time qPCR analysis of Nrf1 and SREBP1 at mRNA expression levels.The results were shown as fold changes (mean ± S.D. n = 3×3) with significant decreases (*, p<0.01; **, p<0.001) relative to the negative controls (NC, with no FBS treatment).(B to F) The free-serum starved HepG2 cells were treated with 10% FBS alone or plus 20 nM RAPA for 0, 12, 24 h, before being subjected to Western blotting with indicated antibodies (B, C, E), in which the intensity of (Fig 5D , d1).By contrast, FBS-stimulated protein expression of Nrf2 was partially suppressed by rapamycin (Fig 5D , d2).However, mRNA expression levels of Nrf1 and Nrf2 were not induced, but rather repressed by FBS, and such repression was partially or completely reversed by rapamycin, as a result of enhanced mRNA expression of Nrf2 by this mTOR inhibitor (Fig 5F and 5G).These data indicate there exists a feedback negative regulatory circuit between mRNA and protein expression of Nrf1 and Nrf2, during stimulation or inhibition of mTOR.
Further examinations of DDI1 -∕-(DDI2 insC ) cells uncovered that, upon the absence of DDI1, the remnant DDI2 were still partially enhanced by FBS, and also partially inhibited by rapamycin (Fig 5E).Thereof, FBS-repressed mRNA expression of DDI2 was fully reversed to a slight increase by rapamycin (Fig 5F and 5G).Similarly, modest stimulation of PSMB5, PSMB6 and PSMB7, abundances by FBS was also partially inhibited by rapamycin (Fig 5E , e3 to e5), but their FBS-repressed mRNA levels were not reversed by rapamycin (Fig 5F and 5G).Such opposite (stimulatory or inhibitory) effects of mTOR on rapamycin-responsive signaling to Nrf1 and downstream proteasome may partially occur in DDI1/2-deficient cells, implying that a DDI1/2-independent mechanism also accounts for this process.

Discussion
The ubiquitin proteasome system is crucial for protein degradation and homeostasis, whilst Nrf1 is a key regulatory factor for governing the transcriptional expression of all proteasome subunits.Of note, the transcriptional activation of proteasomes by mTORC1 may be in an Nrf1-dependent manner, and the mTORC1 signaling to upregulation of Nrf1-targeted proteasomal expression profiles was also considered to occur directly by SREBP1, as reported by Manning's group in 2014's Nature [7].However, a core point from Manning's work on the control of proteasomal proteolysis by mTOR [7] was first challenged by Goldberg's group, arguing that their methodology to measure the rates of protein degradation (labelled by 35 S-Met/Cys rather than by 3 H-Phe) and the former labelled-protein pulse-chase experimental data appear questionable [34], because the resulting data were considered to be rather inconsistent with those well-established discoveries [35,36].Amongst the best-studied actions of mTORC1 are enhancing protein synthesis, and also inhibiting protein degradation by autophagy and proteasomes [35,37].While mTORC1 is inactivated during starvation, an increase in proteolysis and autophagy provides a recycling of amino acids for next protein synthesis and energy production.As such, Manning's group showed that inhibition of mTORC1 activity for 16 h or more resulted in a delayed reduction in overall proteolysis by down-regulating transcriptional expression of proteasomal subunits [7].Similar results were also obtained from 3 H-Phe-labelled pulse-chase experiments in their reply to doubt by Goldberg's group [38].Such discrepant results presented by Manning's and Goldberg's groups are not attributable to nuances in the assays but are inferable due to differences in their chosen culture conditions [38].A higher dose of rapamycin (300 nM, at least 100-fold more than the IC 50 for inhibiting mTORC1) was employed [34] to enable two mTOR kinase complexes (i.e., mTORC1 and mTORC2) to be completely blocked in mouse embryonic fibroblasts (MEFs) with genetic loss of tuberous sclerosis complex 2 (TSC2 -∕-, immunoblots was calculated and shown on the bottom, or real-time qPCR analysis of indicated genes at mRNA levels (D, F).The results were shown as fold changes (mean ± S.D. n = 3×3) with significant decreases (*, p<0.01; **, p<0.001), significant increases ($, p<0.01; $$, p<0.001), or no significant differences (NS), relative to their equivalent controls.These results are representative of at least three independent experiments, each of which was performed in triplicates.https://doi.org/10.1371/journal.pone.0294508.g003that is accompanied by aberrant activation of mTOR).By contrast, a much lower dose (20 nM) of rapamycin for treatment of TSC2 -∕-cells grown in the low-serum conditions [7,38] enabled for specific separation of effects of mTORC1 from mTORC2, as described by [39].Just under this status, it was found that TSC2 -∕--leading activation of mTORC1, rather than mTORC2, stimulates a transcriptional programme involving SREBP1 and Nrf1, leading to an evident enhancement of proteasome-mediated proteolysis exclusively by Nrf1, but not Nrf2 [7,9].Since Manning's work was fantastically well done [7,38] and has gained nearly 200 citations (from the Web of Science at https://www.webofscience.com), it is worth interrogating why no more further experimental evidence confirming their findings has been provided to date by any other groups, so far as we know.Of particular concern is a key issue arising from Manning's work, which merits reexamination of whether mTORC1 signaling to upregulation of Nrf1-targeted proteasomal expression profiles occurs directly by SREBP1 because this controversial mechanism remains obscure.Here, we found that transcriptional expression of Nrf1 and all proteasomal subunits is almost unaffected by SREBP1 (or SREBP2), but conversely, Nrf1 contributes to negative regulation of SREBP1 involved in lipid metabolism ( [40] and this study).Besides, a Yin-Yang relationship between Nrf1 and SREBP2 for maintaining cholesterol homeostasis was elaborately unraveled in Hotamisligil's laboratory [22].Recently, a mechanistic study by Xu's group [41] has shown that activity of SREBPs is inhibited by promoting degradation of SREBP-cleavage activating protein (SCAP, a central sensor for cholesterol) through the protein-ubiquitin E3 ligase RNF5-dependent proteasomal pathway, in this process whereby this ligase is recruited to the endoplasmic reticulum (ER)-localized transmembrane protein 33 (TMEM33), a direct target of Nrf1.Therein TMEM33 is also a downstream effector of pyruvate kinase isoform 2 (PKM2), which coordinates together with p97/ VCP to control the processing of Nrf1 and SREBPs, as well as their bidirectional regulatory ability to dictate lipid metabolism and homeostasis [41].
Because Nrf1 and SREBP1 manifest distinct topobiological behavior around membranes [42], they are endowed with their respective discrepant spatiotemporal partitioning and unique biological functionality to be though exerted, only after being dislocated from the ER into the nucleus so as to regulate distinct sets of target genes.In this study, we have discovered that Nrf1 is not a direct target of SREBP1, albeit both are involved in rapamycin-responsive signaling networks (Fig 6).Of note, the upstream signaling to Nrf1 dislocation by p97 and its processing by DDI1/2, along with downstream proteasomal expression, should be indirectly monitored by potent mTOR signaling networks, to various certain extents, depending on distinct experimental settings in distinct cell types.Therefore, the potential indirect effects of SREBP1 on DDI1/2 and proteasomes cannot be ruled out.Further experimental evidence from DDI1 -∕-(DDI2 insC ) cells demonstrates that putative effects of mTOR on the rapamycin-responsive signaling to Nrf1 and proteasome may also be executed partially through a DDI1/2-independent mechanism, albeit the detailed regulatory events remain to be elucidated.DDI1 -∕-DDI2 insC ) cells were treated with MG132 at 0, 1 or 10 μM for 24 h (G, H) or 4 h (H), and then subjected to Western blotting with distinct antibodies against Nrf1, DDI1 or DDI2.In addition, a long-term exposed image was cropped from part of the corresponding gel (G).These results are representative of at least three independent experiments, each of which was performed in triplicates.https://doi.org/10.1371/journal.pone.0294508.g004 File), no significant changes in transcriptional expression of Nrf1 and other homologous factors (Fig 2E and 2F), as well as almost all proteasomal subunits (S3A and S3B Fig in S2 File), were determined in either

Fig 1 .
Fig 1. Transcriptional expression of Nrf1 and its reporter is unaffected by SREBP1 or rapamycin.(A to D) Two cell lines of HepG2 (A, B) and L7702 (C, D), that had been transfected with: (A, C) siNC (a negative control) or siSREBP1; (B, D) a pSREBP1 expression construct or empty plasmid, were subjected to real-time qPCR analysis of mRNA expression levels of SREBP1 and Nrf1 (n = 3×3; with significant decreases (*, p<0.01), significant increases ($, p<0.01), or no significances (NS)).(E to H) HepG2 cells, that had been transfected with pNrf1-luc (E, F) or pNrf2-luc , we established a DDI1 -∕-cell line by CRISPR-editing with specific gRNA (S4A Fig in S2 File).Further examination of DDI1 -∕-cells by its DNA sequencing, real-time qPCR and Western blotting revealed that two overlapping nucleotide segments of DDI1 were deleted from its two alleles (Fig 4A and S4B Fig in S2 File), but the remnant mRNA levels were expressed (Fig 4B and 4C).This implies there may exist alternative mRNA-splicing and inframe translation start sites to yield two isoforms with distinct molecular weights, as described in yeast DDI1 [29].In addition to DDI1 -∕-, an extra-cytosine base was inserted in the open reading of DDI2 (S4C Fig in S2 File), thus recalled DDI1 -∕-(DDI2 insC ) collectively.This should be a result of DDI1-recognized gRNA targeting the highly conserved sequence of DDI2 (S4A Fig in S2 File).

Fig 2 .
Fig 2. The upstream signaling to Nrf1 and proteasome are to no or fewer degrees, affected in SREBP1-deficient cells.(A to C) HepG2 cells were transfected with siNC or siSREBP1 for 24 h and then subjected to Western blotting with those indicated antibodies.The intensity of immunoblots representing each protein was quantified by the Quantity-One software and shown on the bottom.(D) The mRNA levels of those examined genes were determined by real-time qPCR and shown as fold changes (mean ± S.D. n = 3×3) with significant decreases (*, p<0.01) or significant increases ($, p<0.01) relative to equivalent controls.These results are representative of at least three independent experiments, each of which was performed in triplicates.(E, F)

Fig 4 .
Fig 4. Changed processing of Nrf1 in DDI1/2-deficient cells, but with no different xenograft models.(A) HepG2-derived DDI1 -∕-cells were initially identified by their genomic DNA-sequencing.The results were shown graphically, along with the alignment of two mutant alleles and wild-type (WT).(B, C) In contrast with WT cells, DDI1 -∕-cells were further determined by real-time qPCR (B, shown by mean ± S.D. n = 3×3; *, p<0.01) and Western blotting (C), respectively.(D) No different phenotypes of xenograft tumors in nude mice were observed after murine subcutaneous inoculation of WT and DDI1 -∕-(DDI2 insC ) hepatoma cells.(D) No differences in both tumorigenesis and in vivo growth between WT and DDI1/2-deficient and xenograft tumors were measured in size every two days, before being sacrificed.The results are shown as mean ± S.D. (n = 5).(F) The pathohistological images were obtained by routine HE staining of the aforementioned xenograft tumor tissues.(G, H) Both lines of WT and KO (i.e.